163 related articles for article (PubMed ID: 30965330)
1. Can Biomarkers of Coagulation, Platelet Activation, and Inflammation Predict Venous Thromboembolism in Patients with Haematological Malignancies?
Elmoamly S; Mattar M; Yacoub MF; Afif A
Acta Haematol; 2019; 141(4):245-253. PubMed ID: 30965330
[TBL] [Abstract][Full Text] [Related]
2. Can biomarkers of coagulation, platelet activation, and inflammation predict mortality in patients with hematological malignancies?
Elmoamly S; Afif A
Hematology; 2018 Mar; 23(2):89-95. PubMed ID: 28823228
[TBL] [Abstract][Full Text] [Related]
3. Markers of coagulation activation, inflammation and fibrinolysis as predictors of poor outcomes after pediatric venous thromboembolism: A systematic review and meta-analysis.
Zia A; Russell J; Sarode R; Veeram SR; Josephs S; Malone K; Zhang S; Journeycake J
Thromb Res; 2017 Dec; 160():1-8. PubMed ID: 29078111
[TBL] [Abstract][Full Text] [Related]
4. Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: A review.
Samuelson Bannow BT; Konkle BA
Thromb Res; 2018 Mar; 163():138-145. PubMed ID: 29407626
[TBL] [Abstract][Full Text] [Related]
5. Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer.
Moik F; Prager G; Thaler J; Posch F; Wiedemann S; Schramm T; Englisch C; Mackman N; Pabinger I; Ay C
Arterioscler Thromb Vasc Biol; 2021 Nov; 41(11):2837-2847. PubMed ID: 34470475
[TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study.
Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Hirayama M; Tsuji Y
BMC Cancer; 2017 May; 17(1):351. PubMed ID: 28525975
[TBL] [Abstract][Full Text] [Related]
7. Clinical Impact of Coagulation and Fibrinolysis Markers for Predicting Postoperative Venous Thromboembolism in Total Joint Arthroplasty Patients.
Cheng Y; Liu J; Su Y; Zhao H; Zhao Y; Wen M; Lu S; Zhang W; Wu J
Clin Appl Thromb Hemost; 2019; 25():1076029619877458. PubMed ID: 31608652
[TBL] [Abstract][Full Text] [Related]
8. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor.
Blann AD; Gurney D; Wadley M; Bareford D; Stonelake P; Lip GY
Blood Coagul Fibrinolysis; 2001 Jan; 12(1):43-50. PubMed ID: 11229826
[TBL] [Abstract][Full Text] [Related]
9. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.
Ay C; Vormittag R; Dunkler D; Simanek R; Chiriac AL; Drach J; Quehenberger P; Wagner O; Zielinski C; Pabinger I
J Clin Oncol; 2009 Sep; 27(25):4124-9. PubMed ID: 19636003
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of fibrinolytic markers and venous thromboembolism.
Folsom AR; Cushman M; Heckbert SR; Rosamond WD; Aleksic N
J Clin Epidemiol; 2003 Jun; 56(6):598-603. PubMed ID: 12873656
[TBL] [Abstract][Full Text] [Related]
11. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy.
Lowe G; Woodward M; Vessey M; Rumley A; Gough P; Daly E
Thromb Haemost; 2000 Apr; 83(4):530-5. PubMed ID: 10780311
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for the diagnosis of venous thromboembolism: D-dimer, thrombin generation, procoagulant phospholipid and soluble P-selectin.
Riva N; Vella K; Hickey K; Bertù L; Zammit D; Spiteri S; Kitchen S; Makris M; Ageno W; Gatt A
J Clin Pathol; 2018 Nov; 71(11):1015-1022. PubMed ID: 30093507
[TBL] [Abstract][Full Text] [Related]
13. 28 day post-operative persisted hypercoagulability after surgery for benign diseases: a prospective cohort study.
Ulrych J; Kvasnicka T; Fryba V; Komarc M; Malikova I; Burget F; Brzezkova R; Kvasnicka J; Krska Z; Kvasnicka J
BMC Surg; 2016 Apr; 16():16. PubMed ID: 27048604
[TBL] [Abstract][Full Text] [Related]
14. Safety of anticoagulation in the treatment of venous thromboembolism in patients with haematological malignancies and thrombocytopenia: Report of 5 cases and literature review.
Lim MS; Enjeti AK
Crit Rev Oncol Hematol; 2016 Sep; 105():92-9. PubMed ID: 27397486
[TBL] [Abstract][Full Text] [Related]
15. Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients.
Ay C; Pabinger I
Thromb Res; 2012 Apr; 129 Suppl 1():S6-9. PubMed ID: 22682135
[TBL] [Abstract][Full Text] [Related]
16. Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism.
Pullarkat V; Ngo M; Iqbal S; Espina B; Liebman HA
Br J Haematol; 2002 Sep; 118(4):1166-9. PubMed ID: 12199802
[TBL] [Abstract][Full Text] [Related]
17. Unfavourably altered plasma clot properties in patients with primary Raynaud's phenomenon: association with venous thromboembolism.
Żuk J; Snarska-Drygalska A; Malinowski KP; Papuga-Szela E; Natorska J; Undas A
J Thromb Thrombolysis; 2019 Feb; 47(2):248-254. PubMed ID: 30684190
[TBL] [Abstract][Full Text] [Related]
18. D-dimer levels and risk of recurrent venous thromboembolism.
Eichinger S; Minar E; Bialonczyk C; Hirschl M; Quehenberger P; Schneider B; Weltermann A; Wagner O; Kyrle PA
JAMA; 2003 Aug; 290(8):1071-4. PubMed ID: 12941680
[TBL] [Abstract][Full Text] [Related]
19. Assessing the risk of venous thromboembolism in patients with haematological cancers using three prediction models.
El-Sayed HA; Othman M; Azzam H; Bucciol R; Ebrahim MA; El-Agdar MAMA; Tera Y; Sakr DH; Ghoneim HR; Selim TE
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17771-17780. PubMed ID: 37935936
[TBL] [Abstract][Full Text] [Related]
20. Association of platelet activation markers with cancer-associated venous thromboembolism.
Riedl J; Hell L; Kaider A; Koder S; Marosi C; Zielinski C; Panzer S; Pabinger I; Ay C
Platelets; 2016; 27(1):80-5. PubMed ID: 25970326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
